Generic Jelmyto Availability
Last updated on Apr 10, 2025.
Jelmyto is a brand name of mitomycin, approved by the FDA in the following formulation(s):
JELMYTO (mitomycin - powder;pyelocalyceal)
-
Manufacturer: UROGEN PHARMA
Approval date: April 15, 2020
Strength(s): 40MG/VIAL [RLD]
Is there a generic version of Jelmyto available?
No. There is currently no therapeutically equivalent version of Jelmyto available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Jelmyto. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Material and method for treating internal cavities
Patent 9,040,074
Issued: May 26, 2015
Inventor(s): Holzer Asher & Daniel Dorit & Mullerad Michael & De La Zerda Jaime & Shpolansky Uri & Malchi Nadav & Dollberg Yosh & Tal Dor & Yavin Yossi & Konorty Marina
Assignee(s): Theracoat Ltd.A hydrophilic biocompatible sustained-release material is disclosed. The material comprises amounts of Pluronic F-127, PEG-400, HPMC and water, effective to produce a composition of sufficiently low viscosity at room temperature to be injectable into an internal body cavity via a tube inserted within a urinary catheter. At body temperature, the material exhibits a much higher viscosity and will stably adhere to the internal surface of a body cavity. As the material dissolves, a therapeutic agent incorporated therein is slowly released to the body cavity, while the material itself is excreted from the body.
Patent expiration dates:
- January 20, 2031✓
- January 20, 2031
-
Material and method for treating internal cavities
Patent 9,950,069
Issued: April 24, 2018
Inventor(s): Holzer Asher & Daniel Dorit & Mullerad Michael & De La Zerda Jaime & Shpolansky Uri & Malchi Nadav & Dollberg Yosh & Tal Dor & Yavin Yossi & Konorty Marina
Assignee(s): UROGEN PHARMA LTD.A hydrophilic biocompatible sustained-release material is disclosed. The material comprises amounts of Pluronic F-127, PEG-400, HPMC and water, effective to produce a composition of sufficiently low viscosity at room temperature to be injectable into an internal body cavity via a tube inserted within a urinary catheter. At body temperature, the material exhibits a much higher viscosity and will stably adhere to the internal surface of a body cavity. As the material dissolves, a therapeutic agent incorporated therein is slowly released to the body cavity, while the material itself is excreted from the body.
Patent expiration dates:
- January 20, 2031✓
- January 20, 2031
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- April 15, 2027 - INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH LOW-GRADE UPPER TRACT UROTHELIAL CANCER (LG-UTUC)
More about Jelmyto (mitomycin)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Latest FDA alerts (1)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: antibiotics/antineoplastics
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
